SCHEMBL3902678

SCHEMBL3902678

CCCCCCCCC=Cc1c(O)ccc(C=O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.52
▸ OPRD1 P41143 1/20 0.43
▸ TRPV1 Q8NER1 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ MMP2 P08253 2/20 0.39
▸ F7 P08709 2/20 0.39
▸ F3 P13726 2/20 0.39
▸ FAAH O00519 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ ECE1 P42892 1/20 0.39
▸ SGMS1 Q86VZ5 1/20 0.39
▸ SGMS2 Q8NHU3 1/20 0.39
▸ MUS81 Q96NY9 1/20 0.39
▸ SAE1 Q9UBE0 1/20 0.39
▸ TNNC1 P63316 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ GMNN O75496 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902676 1.00 OPRM1 (0.52) OPRM1OPRD1TRPV1EPHX2MMP2
SCHEMBL3901500 0.78 OPRM1 (0.47) OPRM1OPRD1TRPV1FAAH
SCHEMBL3901498 0.78 OPRM1 (0.47) OPRM1OPRD1TRPV1FAAH
SCHEMBL13562266 0.77 APP (0.48) OPRM1TNNC1
SCHEMBL31545331 0.77 F7 (0.51) OPRM1OPRD1EPHX2MMP2F7
SCHEMBL31546012 0.77 F7 (0.51) OPRM1OPRD1EPHX2MMP2F7
SCHEMBL28810978 0.77 F7 (0.51) OPRM1OPRD1EPHX2MMP2F7
SCHEMBL28947595 0.77 F7 (0.51) OPRM1OPRD1EPHX2MMP2F7
SCHEMBL3915410 0.76 OPRM1 (0.57) OPRM1OPRD1TRPV1FAAHMAPT
SCHEMBL3915407 0.76 OPRM1 (0.57) OPRM1OPRD1TRPV1FAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622598-B2 Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient ARIGEN PHARMACEUTICALS, INC. (JP) 2009-11-24 — — US disclosed
EP-1681280-B1 NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT ARIGEN PHARMACEUTICALS INC (JP) 2009-03-25 — — EP disclosed
US-20070208078-A1 NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT ARIGEN, INC. (JP) 2007-09-06 — — US disclosed
EP-1681280-A1 NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT aRigen, Inc. (JP) 2006-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208078-A1 NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT TYR, H1-3, H1-0 OPRM1 2281/4885OPRD1 1074/4885TRPV1 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback